Medicsight PLC

("Medicsight" or "the Group")

First Quarter Summary Trading Statement

Medicsight plc (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software to assist in the early detection and diagnosis of disease, is pleased to announce its results for the first quarter ended 31 March 2010 which are in line with management expectations at this point in the calendar year.

Highlights

Allan Rowley, Chief Executive of Medicsight PLC commented "During the first quarter of 2010, licence revenue was in line with management's expectations despite being slightly lower than the previous year.

"In January Medicsight signed a global distribution agreement with MEDRAD Inc for our new, automated MedicCO₂LON Insufflator product which distends the colon prior to a CT scan. We have leveraged our key clinical relations in CT colonoscopy to develop MedicCO₂LON, the first 'hardware' product Medicsight has developed to complement its software. We expect sales to commence in the second quarter through MEDRAD's strong commercial and distribution expertise.

"With regards to regulatory approvals we received a second request for Additional Information (AI) from the FDA in January 2010. In conjunction with our FDA advisors, we are currently preparing a response and will shortly submit this to the FDA before the deadline of 20 June 2010. We also await a further update from the Ministry of Health, Labour and Welfare (MHLW) regulatory authorities in Japan.

"Operating expenses have fallen compared to the previous year, as we see the first full quarter of cost savings following the decision last year to reduce headcount and streamline operations.

"We remain in a healthy cash position with a cash balance of £9.1 million at 31 March 2010."

- ENDS -

For further information:

Media enquiries:

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD^™ and LungCAD^™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD^™ and LungCAD^™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.